Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo

Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment of hematological malignancies (blinatumomab), the T cell signaling pathways induced by these molecules are incompletely understood. To gain insight into the mechanism of action for T cell redirection antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Chornoguz, Olesya, Leettola, Catherine N., Leander, Karen, Brosnan, Kerry, Emmell, Eva, Chiu, Mark L., Santulli-Marotto, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918852/
https://www.ncbi.nlm.nih.gov/pubmed/31825302
http://dx.doi.org/10.1089/mab.2019.0035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918852/
https://www.ncbi.nlm.nih.gov/pubmed/31825302
http://dx.doi.org/10.1089/mab.2019.0035

Ejemplares similares